ANI Pharma Q3 revenue $131.8M (+57% YoY); raises FY2023 guidance

ANI PHARMACEUTICALS INC

2023-Q3 EPS reported $0.83 revenue$355,162,000

Record Q3 net revenue $131.8M, up 57.3% YoY; GAAP net income $9.5M ($0.45 diluted EPS).
Adjusted non-GAAP EBITDA $36.5M (+98% YoY); adj. diluted EPS $1.27 vs $0.58 YoY.
Cortrophin Gel net sales $29.7M (+136% YoY); full-year Cortrophin guidance raised to $100M-$107M.
FY2023 revenue guidance raised to $468M-$478M (prev. $425M-$445M); adj. EPS guided $4.29-$4.57.
Generics/Established Brands revenue $102.1M (+43.4% YoY); 5 new products launched in Q3.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ANI PHARMACEUTICALS INC reported the quarter ended September 30, 2023 results: revenue $131.8 million, net income $9.5 million, EPS $0.45. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $131.8 million
Net income: $9.5 million
EPS: $0.45
Guidance: raised
Result: reported results

Exact text from the filing

Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -- -- Record quarterly

View on SEC.gov

Browse all earnings releases →

ANI PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001023024-23-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.